Publicaciones en las que colabora con JUAN CARLOS ALADOS ARBOLEDAS (15)

2023

  1. Anticipatory Antifungal Treatment in Critically Ill Patients with SARS-CoV-2 Pneumonia

    Journal of Fungi, Vol. 9, Núm. 3

  2. Co-02. Estado actual de la hepatitis delta en andalucía. Implantacion del diagnostico en un solo paso.

    Revista andaluza de patología digestiva, Vol. 46, Núm. 5, pp. 298-299

2022

  1. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

    JHEP Reports, Vol. 4, Núm. 5

2021

  1. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

    Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810

  2. Vaccinated patients admitted in icu with severe pneumonia due to sars-cov-2: A multicenter pilot study

    Journal of Personalized Medicine, Vol. 11, Núm. 11

  3. Validación clínica de un test serológico rápido semicuantitativo para pacientes infectados de covid-19 y determinación de la seroprevalencia en una población sanitaria

    Revista española de patología torácica, Vol. 33, Núm. 4, pp. 217-223

2020

  1. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 9, pp. 2354-2362

2019

  1. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals

    AIDS, Vol. 33, Núm. 7, pp. 1167-1174

  2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  3. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 634-641

2018

  1. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis

    PLoS ONE, Vol. 13, Núm. 7

2017

  1. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2016

  1. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain

    Journal of Infection, Vol. 72, Núm. 2, pp. 152-160

2014

  1. Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort

    International Journal of Infectious Diseases, Vol. 26, pp. 83-87

2012

  1. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 1, pp. 472-478